公开(公告)号：WO2021259195A1

公开(公告)日：2021-12-30

申请号：PCT/CN2021/101213

申请日：2021-06-21

Applicant: 四川大学华西医院 ,  四川辉阳生命工程股份有限公司

Inventor： 刘伦旭 ,  李川 ,  魏光文

IPC: A61K38/21 ,  A61K31/427 ,  A61K31/4045 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61K38/212

Abstract: 一种联合用药物或试剂盒及其在制备用于治疗新型冠状病毒肺炎或中东呼吸综合征的药物中的用途，该联合用药物或试剂盒含有同时或分别给药的rSIFN-co与基线治疗药物，其中基线治疗药物是：1)洛匹那韦利托那韦；或2)阿比多尔；该联合用药物可有效改善中度至重度COVID-19患者的病情。

公开(公告)号：WO2021196546A1

公开(公告)日：2021-10-07

申请号：PCT/CN2020/119364

申请日：2020-09-30

Applicant: 南开大学

Inventor： 张拥军 ,  王远鹏 ,  关英

IPC: A61M37/00 ,  A61K9/70 ,  A61K47/34 ,  A61K47/36 ,  A61K38/28 ,  A61K38/21 ,  A61K38/38 ,  A61K38/212 ,  A61K9/0021 ,  A61M2037/0046 ,  A61M2037/0053 ,  A61M37/0015

Abstract: 本发明提供了一种用于蛋白质类药物快速透皮递送的微针阵列及其制备方法，属于生物医药技术领域，所述微针阵列的结构包括微针阵列基底与沉积在微针表面的载药释放层，所述载药释放层由蛋白质药物与阴离子聚电解质通过静电相互作用形成的层层自组装膜组成。本发明制备的微针阵列使用简单方便，施用时间短，仅为10s～1min，施用后即取走，方便患者自我给药，具有微创、无痛的特点，可提高病人依顺性。药物释放迅速，可获得与普通皮下注射相当的药代动力学和药效学。

公开(公告)号：WO2023060188A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/077690

申请日：2022-10-06

Applicant: CYTOMX THERAPEUTICS, INC.

Inventor： BEREZHNOY, Alexey Yevgenyevich ,  LAPUYADE, Nicole G. ,  CAI, Na ,  WINTER, Michael B. ,  WONG, Kenneth ,  PAIDHUNGAT, Madan M. ,  DANIEL, Dylan L. ,  LE SCOLAN, Erwan

IPC: A61K38/21 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/00 ,  C07K19/00 ,  A61K38/212 ,  A61K39/39 ,  A61K39/39558 ,  C07K14/52 ,  C07K16/2827 ,  C07K2319/00

Abstract: Provided herein are methods of treating a subject by administering a combination of an activatable cytokine construct (ACC) and a PD-1/PD-L1 pathway inhibitor in which the ACC includes: a first monomer construct including an optional first peptide mask (PM1), an optional third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and a second monomer construct including an optional second peptide mask (PM2), an optional forth cleavable moiety (CM4), a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), wherein the CM2 is positioned between the CP2 and the DD2; wherein the DD1 and the DD2 bind to each other thereby forming a dimer of the first monomer construct and the second monomer construct; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

公开(公告)号：WO2021141919A1

公开(公告)日：2021-07-15

申请号：PCT/US2021/012211

申请日：2021-01-05

Applicant: PRINCIPIA BIOPHARMA INC.

Inventor： NUNN, Philip ,  LANGRISH, Claire ,  THOMAS, Dolca

IPC: A61K31/519 ,  A61P37/06 ,  A61K45/06 ,  A61K31/145 ,  A61K31/42 ,  A61K31/436 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/655 ,  A61K31/675 ,  A61K38/212 ,  A61K38/217 ,  A61K39/3955 ,  A61K9/0053 ,  A61P13/12 ,  A61P37/02

Abstract: The present disclosure provides methods of treating a disease chosen from membranous nephropathy (MN), IgG4-related diseases, and antiphospholipid syndrome (APS) in a mammal using, e.g., a therapeutically effective amount of, the BTK inhibitor 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2022175651A1

公开(公告)日：2022-08-25

申请号：PCT/GB2022/050406

申请日：2022-02-16

Applicant: ILC THERAPEUTICS LIMITED

Inventor： STIMSON, William

IPC: A61K38/21 ,  A61P31/14 ,  C07K14/56 ,  A61K38/212 ,  C07K2319/00

Abstract: The present invention relates to a composition comprising an interferon alpha (IFN-α) subtype which is a hybrid of IFN-α10 and IFN-α14 for use in the prevention or treatment of a viral infection, as well as a method of treatment and/or prophylaxis of a viral infection using said IFN-α hybrid.

公开(公告)号：WO2022094330A2

公开(公告)日：2022-05-05

申请号：PCT/US2021/057433

申请日：2021-10-29

Applicant: NAGY, Aurangzeb Nafees

Inventor： NAGY, Aurangzeb Nafees

IPC: A61K31/15 ,  A61K31/198 ,  A61K31/352 ,  A61K31/4045 ,  A61K38/21 ,  A61P11/00 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217

Abstract: A method of treating acute respiratory failure (ARF) and/or acute respiratory distress syndrome (ARDS) (optionally caused in a subject afflicted with COVID-19) in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition or combination including a tetrahydrocannabinol (THC), derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof and, optionally, one or more of an interferon (IFN), derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof, a fluvoxamine, derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof, an acetylcysteine, derivative, intermediate, metabolite, or fragment thereof, and/or combinations thereof.

公开(公告)号：WO2021239165A2

公开(公告)日：2021-12-02

申请号：PCT/CU2021/050004

申请日：2021-05-27

Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

Inventor： PEREA RODRÍGUEZ, Silvio, Ernesto ,  PERERA NEGRÍN, Yasser ,  RAMÓN SÁNCHEZ, Ailyn, de la Caridad ,  CABALLERO MENÉNDEZ, Evelin ,  GUILLEN NIETO, Gerardo, Enrique ,  FERNÁNDEZ ORTEGA, Celia, Berta

IPC: A61K38/16 ,  A61K38/21 ,  A61K31/4196 ,  A61K31/5025 ,  A61K31/426 ,  A61P31/14 ,  A61K38/212 ,  A61K38/217

Abstract: Péptido para el tratamiento o la prevención de infecciones originadas por coronavirus que se caracteriza porque posee una secuencia de aminoácidos identificada como SEQ ID NO: 1. Composición farmacéutica para el tratamiento o la prevención de dichas infecciones que se caracteriza porque comprende el mencionado péptido. Combinación farmacéutica para el tratamiento de infecciones originadas por coronavirus que se caracteriza porque comprende una composición que comprende el péptido cuya secuencia de aminoácidos se identifica como SEQ ID NO: 1 y un medicamento antiviral. La invención también comprende el uso del péptido para la fabricación de un medicamento para el tratamiento o la prevención de infecciones originadas por coronavirus, y métodos de tratamiento con dicho péptido.

公开(公告)号：WO2021263205A1

公开(公告)日：2021-12-30

申请号：PCT/US2021/039248

申请日：2021-06-25

Applicant: CV6 THERAPEUTICS (NI) LIMITED

Inventor： MULLIGAN, Karl Andrew ,  WILSON, Peter Michael ,  WILSON, Melissa J LaBonte ,  LADNER, Robert D.

IPC: A61K31/4164 ,  A61K31/4168 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/496 ,  A61K31/433 ,  A61K31/5377 ,  A61K31/41 ,  A61K31/422 ,  A61K31/4192 ,  A61K31/4184 ,  A61K31/541 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61K31/7072 ,  A61K45/06 ,  A61K35/17 ,  A61K38/12 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/212 ,  A61K39/39558 ,  C07K16/2818

Abstract: Provided herein are deoxyuridine triphosphatase (dUTPase) inhibitors for use in methods of enhancing a therapeutic efficacy of an immunotherapy agent in a subject in need thereof and in methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject an effective amount of a deoxyuridine triphosphatase (dUTPase) inhibitor and the immunotherapy agent, and optionally further comprising administering to the subject one or more selected from an effective amount of an inhibitor of thymidylate biosynthesis, and an effective amount of an anthracycline or other topoisomerase II inhibitor.

公开(公告)号：WO2021191456A1

公开(公告)日：2021-09-30

申请号：PCT/EP2021/058041

申请日：2021-03-26

Applicant: VECTURA LIMITED

Inventor： MANFORD, Fergus

IPC: A61K31/4706 ,  A61K31/7052 ,  A61K38/21 ,  A61P11/00 ,  A61K9/00 ,  A61K47/26 ,  A61K38/212 ,  A61K38/215 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008

Abstract: The present disclosure relates to the administration of a composition comprising an interferon, azithromycin and chloroquine for the treatment of respiratory conditions.

公开(公告)号：WO2020252441A2

公开(公告)日：2020-12-17

申请号：PCT/US2020/037704

申请日：2020-06-15

Applicant: GUMRUKCU, Serhat

Inventor： GUMRUKCU, Serhat

IPC: A61K35/17 ,  C12N5/0783 ,  A61P31/18 ,  A61K31/138 ,  A61K31/415 ,  A61K31/5415 ,  A61K31/616 ,  A61K31/664 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/212 ,  A61P35/00

Abstract: Provided herein are methods for treating a patient with HIV, cancer, a viral infection, or a bacterial infection, comprising administering an effective amount of activated lymphocytic cellular compositions, Related compositions, kits, and methods for modulating the immune system using the activated lymphocytic cellular compositions are also provided.